Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma |
| |
| Authors: | Joshua Richter Larysa Sanchez Noa Biran C.K. Wang Kathryn Tanenbaum Victoria DeVincenzo Brooke Grunman David H. Vesole David S. Siegel Andrew Pecora Stuart L. Goldberg |
| |
| Affiliation: | 1. Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY;2. John Theurer Cancer Center, Hackensack, NJ;3. COTA Inc, Boston, MA;1. Department of Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey;2. Department of Hematology, Faculty of Medicine, Ondokuz May?s University, Samsun, Turkey;1. Division of Medical Oncology, University of Washington Medicine, Seattle, WA;2. Clinical Research Division, Fred Hutch Cancer Research Center, Seattle, WA;3. Department of Hospital and Specialty Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, WA;4. Division of Hematology;5. Division of Nuclear Medicine, Department of Radiology;6. Department of Pathology, University of Washington Medicine, Seattle, WA;1. Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK;2. Myeloma Laboratory, The Institute of Cancer Research, Sutton, UK;3. Myeloma UK, Edinburgh, UK;4. Perlmutter Cancer Center, NYU Langone Health, New York, NY;5. Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK;6. Department of Haematology, Southampton General Hospital, Southampton, UK;1. Real-world Evidence/Data Analytics Center of Excellence, Pharmerit International LP, Bethesda, MD;2. Market Access, Taiho Oncology, Princeton, NJ;3. Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven, New Haven, CT;1. Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy;2. Health Physics Department, ASST-Spedali Civili, Brescia, Italy;1. Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA;2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;3. Institute of Hematology, University of Bologna, Bologna, Italy;4. Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;5. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH;6. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA;7. Department of Medicine-Hematology and Oncology, University Hospital/Case Western Reserve Medical Center, Cleveland, OH |
| |
| Abstract: | BackgroundAdvances in the management of multiple myeloma (MM) have extended survival and reduced painful skeletal-related events. As MM is evolving toward a chronic disease, we sought to determine the prevalence of self-reported symptom burden and psychological distress, and to determine the association of distress with survival.MethodsThe CPASS-7 patient-reported outcome instrument was administered to a convenience sample of MM patients at 7 outpatient cancer centers.ResultsA total of 239 patients completed the CPASS-7 between September 2015 and October 2016%; 57% of respondents were male, and median age was 67 years. Forty-eight percent were concerned that they could not do the things they wanted to do, with 33% reporting decreased performance status. Financial toxicity concerns were self-reported by 44%, with family burdens noted in 24%. Although depression was reported by only 15%, 41% noted lack of pleasure. Pain was a concern in 36%. With a median follow-up of 316 days since CPASS-7 completion, 13% of patients had died. A high total distress score was noted in 57 (24%) and trended toward an association with a decreased survival rate compared to the 182 patients (76%) with a low total distress score (P = .066). The 6-month survival rates for patients with high and low distress scores were 86% and 96%, respectively, and 12-month survival rates were 76% and 87%, respectively.ConclusionDespite dramatic improvements in survival among patients with MM, symptom, financial, and psychosocial concerns continue to be major patient concerns. As MM becomes a chronic disease, additional attention to addressing these issues is required. |
| |
| Keywords: | End-of-life Palliative care Patient-reported outcomes Plasma cell dyscrasia PRO QOL |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
